Targeted therapy medicines for larynx cancer treatment are designed to specifically target certain molecules or proteins that are involved in the growth and spread of cancer cells. Unlike chemotherapy, which can affect both cancerous and healthy cells, targeted therapies aim to attack cancer cells while sparing healthy cells.

Here are some examples of targeted therapy medicines used in the treatment of larynx cancer:

1. Cetuximab:
   This is an antibody that targets the epidermal growth factor receptor (EGFR) on the surface of cancer cells. By blocking EGFR, cetuximab can slow down or stop the growth and spread of cancer cells. Cetuximab is often used in combination with radiation therapy to treat larynx cancer.

2. Pembrolizumab:
   This is an immune checkpoint inhibitor that targets the programmed death-1 (PD-1) protein on immune cells. By blocking PD-1, pembrolizumab can help the immune system recognize and attack cancer cells. Pembrolizumab may be used alone or in combination with chemotherapy to treat larynx cancer.

3. Erlotinib:
   This is a small molecule inhibitor that targets the EGFR protein inside cancer cells. By blocking EGFR, erlotinib can slow down or stop the growth and spread of cancer cells. Erlotinib is typically used in patients with advanced larynx cancer who have already received chemotherapy.

It is important to note that targeted therapy medicines may not be suitable for all patients with larynx cancer. Treatment options should be discussed with a healthcare provider who can determine the best course of action based on the patient’s individual case.

Immunotherapy medicines have emerged as an important class of drugs for the treatment of various types of cancer, including larynx cancer. These drugs work by enhancing the ability of the patient’s immune system to recognize and attack cancer cells. Here are some examples of immunotherapy medicines used in the treatment of larynx cancer:

1. Pembrolizumab:
   This is an immune checkpoint inhibitor that targets the programmed death-1 (PD-1) protein on immune cells. By blocking PD-1, pembrolizumab can help the immune system recognize and attack cancer cells. Pembrolizumab may be used alone or in combination with chemotherapy to treat larynx cancer.

2. Nivolumab:
   This is another immune checkpoint inhibitor that targets the PD-1 protein. Nivolumab may be used alone or in combination with other drugs to treat larynx cancer that has spread or come back after previous treatment.

3. Durvalumab:
   This is an immune checkpoint inhibitor that targets the programmed death ligand-1 (PD-L1) protein on cancer cells. By blocking PD-L1, durvalumab can prevent cancer cells from evading the immune system. Durvalumab may be used alone or in combination with chemotherapy to treat larynx cancer.

4. Atezolizumab:
   This is an immune checkpoint inhibitor that targets the PD-L1 protein. Atezolizumab may be used alone or in combination with chemotherapy to treat larynx cancer that has spread or come back after previous treatment.

It is important to note that immunotherapy medicines may not be suitable for all patients with larynx cancer. Treatment options should be discussed with a healthcare provider who can determine the best course of action based on the patient’s individual case. Additionally, these drugs can have side effects that should be monitored and managed by a healthcare professional.

Steroids may be used to help reduce inflammation and swelling caused by cancer or cancer treatment.